2011
DOI: 10.1007/s12094-011-0618-9
|View full text |Cite
|
Sign up to set email alerts
|

Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer

Abstract: The administration of gemcitabine, associated with oral tegafur and leucovorin, has activity against advanced pancreatic cancer, with an adequate toxicity profile.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2012
2012
2012
2012

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 28 publications
0
1
0
Order By: Relevance
“…Therefore, the EGFR inhibitor is currently FDA-approved for use in combination with gemcitabine for the treatment of pancreatic cancer. Other agents of interest include curcumin (a natural product) [6], leucovorin (an adjuvant agent) [6], tegafur (a prodrug of 5-FU) [148,149], and MGCD0103 and valproic acid (HDAC inhibitors) [150]. In particular, notable combinations under study include GTX (gemcitabine, docetaxel, and capecitabine) [151,152], GemOx (gemcitabine, oxaliplatin) [153], GemOxCet (gemcitabine, oxaliplatin, cetuximab), and Gemoxel (gemcitabine, oxaliplatin, capecitabine) [154].…”
Section: Novel Therapeutic Combinations With Gemcitabinementioning
confidence: 99%
“…Therefore, the EGFR inhibitor is currently FDA-approved for use in combination with gemcitabine for the treatment of pancreatic cancer. Other agents of interest include curcumin (a natural product) [6], leucovorin (an adjuvant agent) [6], tegafur (a prodrug of 5-FU) [148,149], and MGCD0103 and valproic acid (HDAC inhibitors) [150]. In particular, notable combinations under study include GTX (gemcitabine, docetaxel, and capecitabine) [151,152], GemOx (gemcitabine, oxaliplatin) [153], GemOxCet (gemcitabine, oxaliplatin, cetuximab), and Gemoxel (gemcitabine, oxaliplatin, capecitabine) [154].…”
Section: Novel Therapeutic Combinations With Gemcitabinementioning
confidence: 99%